Notice Number: NOT-HL-18-660
Release Date: October 23, 2018
Response Date : New Date - March 15, 2019 as per issuance of NOT-HL-19-672 (old response date - January 25, 2019)
National Heart, Lung, and Blood Institute (NHLBI)
In 2015, the National Heart, Lung, and Blood Institute (NHLBI) formed the NHLBI Women’s Health Working Group (WHWG) to collaborate with the NIH Office of Research on Women’s Health and other trans-NIH initiatives to pursue a better understanding of the health of women through behavioral and biomedical research. More specifically the NHLBI WHWG goals are to: (1) understand mechanisms of heart (and vascular), lung, hematologic (blood), and sleep (HLBS) diseases that present only in women, or are more prevalent in women than in men, and their interaction with the broader environment; (2) improve the execution of existing policies on women in clinical trials, and strengthen collaborations with other agencies and NIH Institutes who perform clinical trials; (3) support the development of a diverse workforce with increased participation of women throughout the training and career pipeline; (4) increase public awareness of institutional efforts centered on research into women’s health and (5) serve as a resource for information on topics related to women’s health.
Major progress has been made in achieving a balance of men and women in human studies. However, scientific needs persist in understanding the underlying mechanisms that increase women’s risk or resilience for certain HLBS diseases. Also, mechanisms that mediate the almost exclusive or specific manifestation of certain HLBS diseases in women, and/or that could explain sex/gender differences in response to treatment of HLBS diseases and their related adverse events are still not fully understood. Uncovering these mechanisms will set a stronger foundation upon which to build clinical research focused on more effective prevention and treatment strategies for HLBS diseases and disorders in women.
This Request for Information (RFI) seeks input from the research community (academia and industry), health care professionals, patient advocates, representatives of health advocacy organizations, members of scientific or professional organizations, and other interested stakeholders on the following topics regarding mechanisms of sex differences of HLBS diseases and disorders, and specifically women’s susceptibility or resilience to these.
Public comment is sought for, but not limited to the following:
All responses to this RFI must be submitted via email to WHWGRFI@nhlbi.nih.gov by January 25, 2018. Please include the Notice number (NOT-HL-18-660) in the subject line.
Responses to this RFI are voluntary. Do not include any proprietary, classified, confidential, or sensitive information in your response. The NIH will use the information submitted in response to this RFI at its discretion and will not provide comments to any responder's submission. The collected information will be reviewed by NIH staff, may appear in reports, and may be shared publicly on an NIH website.
The Government reserves the right to use any non-proprietary technical information in summaries of the state of the science, and any resultant solicitation(s). The NIH may use the information gathered by this RFI to inform the development of future funding opportunity announcements.
This RFI is for information and planning purposes only and should not be construed as a solicitation or as an obligation on the part of the Federal Government, the National Institutes of Health (NIH), or individual NIH Institutes and Centers. No basis for claims against the U.S. Government shall arise as a result of a response to this request for information or from the Government’s use of such information.
Please direct all inquiries to: